Connect with us

Tech

Regenerative Aesthetics Firm Suneva Medical Gets SPAC Support to Go Public

Published

on

Skip to main content

Share:

Suneva Medical Inc, medical aesthetics player, will soon form a reverse merger with Viveon Health Acquisition Corp (NYSE: VHAQ), a special purpose acquisition company.

Viveon Health went public through an initial public offering in December 2020 that brought in proceeds of $201 million.
Deal Details: Once its reverse merger with Suneva has gotten the go-ahead, the companies will combine and begin trading on the New York Stock Exchange under the ticker symbol ‘RNEW.’
Under the terms of the deal, Viveon Health will issue 25 million shares to Suneva’s current security holders, plus up to another 12 million shares if the combined company’s share price hits certain benchmarks in the five years after the transaction closes.
Once the SPAC deal has gone through, the resulting public company is expected to have a pro forma equity value of about $511 million.
Company Overview: Suneva develops, manufactures and commercializes solutions for the medical aesthetics market.
The company’s portfolio includes minimally invasive solutions that utilize the body’s restorative capacity in non-surgical outpatient treatment settings to deliver immediate aesthetic results.
Suneva has expanded the company’s product portfolio during the last 18 months to yield a greater than 40% Y/Y revenue growth with an anticipated revenue CAGR of approximately 50% between 2020-2024.

Related Articles (VHAQ)

View the discussion thread.

Posted-In: BriefsBiotech M&A News Health Care Financing IPOs General

Need newswire data?
Click here to see licensing options.

Subscribe to:

Benzinga Premarket Activity

Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.

Market in 5 Minutes

Everything you need to know about the market – quick & easy.

Fintech Focus

A daily collection of all things fintech, interesting developments and market updates.

SPAC

Everything you need to know about the latest SPAC news.

Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Read More

Source: benzinga.com

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Tech

WHO Recommends Glaxo, Eli Lilly Drugs for COVID-19 Treatment Amid Omicron Surge

Published

on

Skip to main content

Share:

An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc (NYSE: GSK) / Vir Biotechnology Inc (NASDAQ: VIR) for COVID-19 patients.

In its guidelines published in the British Medical Journal, the panel has recommended Lilly’s baricitinib (Olumiant), a Janus kinase (JAK) inhibitor, combined with corticosteroids for severe COVID-19 patients.
The panel also conditionally recommended sotrovimab, a monoclonal antibody developed by GSK / Vir, for patients with non-severe COVID-19 at the highest risk of hospitalization.
Related:WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients.
While the global body has already approved the monoclonal antibodies casirivimab with Imdevimab from Regeneron Pharmaceuticals Inc (NASDAQ: REGN), it has found insufficient data to recommend one treatment over another from that class of medications.
The panel also noted that the activity of these drugs against new variants of the virus, such as Omicron remained uncertain and said it would update the guidelines once new data are available.
Price Action: GSK shares are up 0.88% at $45.46, VIR shares are down 2.87% at $36.57, and LLY stock is down 1.59% at $245.69 during the market session on the last check Friday.

Related Articles (GSK + VIR)

GSK, Vir Biotech File For Emergency Use Nod For Intramuscular Sotrovimab For COVID-19

Vir Biotechnology Expands Partnership With Bill & Melinda Gates Foundation, Launches New Antibody Research Initiative Aimed At A Functional Cure For HIV And Prevention Of Malaria; Foundation Has Committed $40M Equity Investment And $10M Grant

Adagio’s COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies

20 Stocks Moving in Thursday’s Pre-Market Session

50 Biggest Movers From Yesterday

US To Purchase 600K Additional Doses of GSK-Vir’s COVID-19 Antibody Therapy

View the discussion thread.

Posted-In: Briefs COVID-19 CoronavirusBiotech Government News Health Care General

Read More

Source: benzinga.com

Continue Reading

Tech

ST Imaging’s ViewScan 4 Microfilm Scanner Wins 2022 Platinum Modern Library Award

Published

on

Northbrook, IL, Jan. 14, 2022 (GLOBE NEWSWIRE) — For an eighth straight year, ST Imaging’s ViewScan 4 microfilm scanner has been recognized for a Platinum Modern Library Awards (MLAs) from LibraryWorks. ST Imaging, a Digital Check brand, is a worldwide leader in the design and manufacturing of digital microfilm viewer/scanners, and the only microfilm scanner manufacturer to have continuously received the Platinum MLA for all eight years.

“We are thrilled to be recognized again as a leading microfilm scanner in the library market by librarians,” says Matt Anderson, Vice President of Sales and Marketing for ST Imaging. “We are dedicated to continue to develop and enhance the user experience of the ViewScan 4 and PerfectView software.”

When designing the ViewScan 4 and PerfectView software, we received direct feedback from the industry on how to implement those features and how to make them easy to use. The result is a simplified, color-coded, streamlined user experience that makes working with microfilm fast and fun. While older reader/printers and other microfilm scanners can be difficult to use, the ViewScan makes loading and scanning film quick, fun, and easy. The ViewScan also allows users to share their discoveries like never before.

At ST Imaging, we understand that most customers are not experts in the field of digital image capture. Our system describes our camera size as we expect most of our customers to understand it, as you would for a cellphone or digital camera. The ViewScan 4 is equipped with a native 18-megapixel image sensor. That means there are 18 million pixels capturing the focused light providing an image instantly to the monitor. Competitive scanners may use a different definition for their camera. Be sure you have accurate information of the image sensor on the camera in your microfilm scanner and if you have any doubt, request a side-by-side comparison.

Jenny Newman, publisher and MLA program manager said, “It’s great to see ST Imaging and their ViewScan 4 be recognized year after year as a leading microfilm scanner in the library market.”

The MLAs were created to recognize top products in the library industry in a truly unbiased format. Products were submitted by companies, collected by LibraryWorks which distributes them to their database of more than 80,000 librarians at public, K-12, academic, and special libraries. Only customers who have had experience with these products in their facilities were permitted to judge the products, resulting in a truly unbiased score.

About ST Imaging

ST Imaging is a leading worldwide manufacturer and distributor of micrographic equipment and other collection scanning solutions. Founded in 1989, the company was acquired in 1999 by Digital Check Corp. In 2004, ST Imaging introduced the revolutionary ST200 digital film scanner, changing the way library customers view film.

The company’s flagship product, the ViewScan film scanner set the standard for making film scanning easy and assessable to the public. ViewScan systems incorporate the latest technology to improve viewing, scanning, editing, and sharing of microfilm within libraries, schools, government, business, and other collections.

The ST Imaging headquarters and manufacturing are in Meridian, ID. Scanners are available through a worldwide network of authorized resellers and are supported by ST Imaging’s comprehensive fulfillment, training, support, warranty, and repair services.

About LibraryWorks

LibraryWorks helps administrators to make informed decisions about library technology, automation and software, collection development and management, facilities and furnishings, staffing, purchasing, and other areas that drive effective strategic planning and day-to-day operations. Our family of resources can enable you to identify best practices, monitor trends, evaluate new products and services, apply for grants and funding, post or find a job, and even enjoy some library humor.

About the Modern Library Awards program

The Modern Library Awards (MLAs) is a program designed to recognize elite products and services in the library market which can help library management personnel enhance the quality-of-experience for the library user and increase the performance of their library systems.

ViewScan 4 Microfilm Reader
Modern Library Awards

Matt Anderson
ST Imaging
208-514-4000
manderson@stimaging.com
Read More

Original Article: benzinga.com

Continue Reading

Tech

Vermont Lawmakers File Drug Decriminalization Bill, Here’s What’s in It

Published

on

It seems that Vermont is on its way to decriminalizing all drugs, as the state’s Democratic and Progressive lawmakers filed a new bill this week to decriminalize their possession.

Reps. Logan Nicoll (D) and Selene Colburn (P) introduced the legislation, which is seen as a harm reduction tool that can also help address racial disparities in enforcement, Marijuana Moment reported.

What’s In The New Bill?

The measure would make possession and distribution of personal-use amounts of currently illicit drugs punishable by a $50 fine – without a threat of a prison sentence or being subject to a substance use screening and health service.

In addition, if the amount of the drug in question is under a “benchmark personal use” threshold – previously set by a new Drug Use Standards Advisory Board – people would face a civil penalty once the bill amends the state statute on drug possession and distribution.

According to the new policy, the board would include “experts in the fields of general and behavioral health care, substance use disorder treatment, and drug user communities.”

Moreover, criminal penalties for sharing small amounts of currently illicit drugs without compensation would be removed.

So far, nearly one-third of the Vermont House, or 40 initial cosponsors, support the proposal.

Colburn told Marijuana Moment in an interview this week that the goal is to streamline the process of legalization in a way that lawmakers in other states have, citing Maine as an example.

The legislator said that she’s been “talking with a lot of frontline folks, a lot of people with lived experience, and the vast majority of those folks will share that justice system involvement has been a hurdle and a barrier in their recovery, or even just their access to life-saving medication or to harm reduction tools.”

Colburn added that in their discussions, she and her colleagues are trying to be clear that the vast majority of people who are drug users are not struggling with substance use disorder. “So this is definitely a civil liberties issue as well. But for folks who [do have substance misuse disorders], the impacts of criminalization have caused, and continue to cause, so much harm.”

Related News

Photo: Courtesy of Colin Davis on Unsplash

Read More

Source: benzinga.com

Continue Reading

Trending

BaypointNews.com